1. Scrip
  2. >>Business
  3. >>Deals

Caladrius Takes Former Baxalta Angina Program Off Shire's Hands

 
• By Lucie Ellis-Taitt

Shire has divested a cell therapy program for angina it picked up via the acquisition of Baxalta in 2016; Caladrius hopes to bring the Phase III treatment to the US market soon.

Anatomy of Human Heart
Shire licenses angina cell therapy to Caladrius

Caladrius Biosciences Inc., a clinical-stage biopharma developing therapies for autoimmune and select cardiology indications, has acquired from Shire PLC a late-stage cell therapy program for refractory angina.

Caladrius has purchased the exclusive worldwide development and regulatory rights for Shire's CD34+ cell therapy program for the treatment of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 
• By Anju Ghangurde

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 
• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Merck & Co. Remains In The BD Game After Verona Takeout

 
• By Jessica Merrill

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.

Asia Deal Watch: JCR And Alexion Build Upon Existing Gene Therapy Alliances

 
• By Joseph Haas, Lisa Takagi, Sushmita Panda, and Anju Ghangurde

Plus deals involving TandemAI/Perpetual Medicines, Biocytogen/BeOne, Chugai/Gero, CStone/Istituto Gentili, Alembic/Utility, Brii/Joincare, HanchorBio/Henlius, Rakuten/Cyntec and more.

More from Business